EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belluzzi, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Belluzzi, A.
Evidence-Based Medicine 2002; 7:186
© 2002 Evidence-Based Medicine

Therapeutics

Review: infliximab increases response and remission rates in fistulising or treatment-resistant Crohn’s disease

Marshall JK, Blackhouse G, Goeree R, et al.Infliximab for the treatment of Crohn’s disease: a systematic review and cost-utility analysis. Technology report no. 24. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2002. http://www.ccohta.ca.

QUESTION: In patients with fistulising or treatment-resistant Crohn’s disease, is infliximab safe and effective?

The first 150 words of the full text of this article appear below.

Data sources
Studies were identified by searching Medline, EMBASE/Excerpta Medica, Current Contents, CINAHL, HealthSTAR, TOXLINE, the Cochrane Library, Drug Info Full Text, Pharmaceutical & Health Care Industry News, PharmaProjects, and Pharmaceutical News Index (1990 to May 2001). Scientific meeting abstracts were searched; major clinical gastroenterology journals were hand searched (to August 2001); and authors, government agencies, and pharmaceutical companies were contacted.

Study selection
2 reviewers independently selected English-language randomised controlled trials (RCTs) that reported clinical end points for infliximab treatment in adults with fistulising or treatment-resistant Crohn’s disease.

Data extraction
2 independent reviewers extracted data on study centres, source of funding, patients, treatment regimens, quality of study methods, and outcomes (response, remission, and fistula closure).

Main results
4 RCTs met the selection criteria. Fistulising Crohn’s disease: 1 RCT (n = 94) showed that more patients in the infliximab groups than in the placebo group had >=50% closure. Treatment-resistant Crohn’s disease: RCTs of treatment-resistant Crohn’s disease were too heterogeneous . . . [Full text of this article]

Andrea Belluzzi, MD

S. Orsola Hospital, Bologna, Italy






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2002 by the BMJ Publishing Group Ltd.